- Home
- MODD vs GUTS Comparison
MODD vs GUTS Comparison
Compare MODD & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- GUTS
- Stock Information
- Founded
- MODD 1998
- GUTS 2010
- Country
- MODD United States
- GUTS United States
- Employees
- MODD N/A
- GUTS N/A
- Industry
- MODD Industrial Specialties
- GUTS
- Sector
- MODD Health Care
- GUTS
- Exchange
- MODD Nasdaq
- GUTS NYSE
- Market Cap
- MODD 46.3M
- GUTS 58.8M
- IPO Year
- MODD N/A
- GUTS 2024
- Fundamental
- Price
- MODD $0.86
- GUTS $1.95
- Analyst Decision
- MODD
- GUTS Buy
- Analyst Count
- MODD 0
- GUTS 1
- Target Price
- MODD N/A
- GUTS $10.00
- AVG Volume (30 Days)
- MODD 78.5K
- GUTS 253.9K
- Earning Date
- MODD 06-20-2025
- GUTS 05-13-2025
- Dividend Yield
- MODD N/A
- GUTS N/A
- EPS Growth
- MODD N/A
- GUTS N/A
- EPS
- MODD N/A
- GUTS N/A
- Revenue
- MODD N/A
- GUTS $60,000.00
- Revenue This Year
- MODD N/A
- GUTS N/A
- Revenue Next Year
- MODD N/A
- GUTS N/A
- P/E Ratio
- MODD N/A
- GUTS N/A
- Revenue Growth
- MODD N/A
- GUTS N/A
- 52 Week Low
- MODD $0.68
- GUTS $0.87
- 52 Week High
- MODD $2.65
- GUTS $7.05
- Technical
- Relative Strength Index (RSI)
- MODD 39.61
- GUTS 56.42
- Support Level
- MODD $0.75
- GUTS $1.66
- Resistance Level
- MODD $0.90
- GUTS $1.97
- Average True Range (ATR)
- MODD 0.07
- GUTS 0.17
- MACD
- MODD -0.01
- GUTS -0.00
- Stochastic Oscillator
- MODD 39.29
- GUTS 49.31
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.